Loss-of-function analysis reveals distinct requirements of the translation initiation factors
eIF4E, eIF4E-3, eIF4G and eIF4G2 in Drosophila spermatogenesis.
Inhibition of translation initiation factors
might be the potential therapeutic targets for HCV patients with hepatic iron overload.
Canonical initiation is a complex process utilizing more than 25 proteins, including a minimum of twelve eukaryotic initiation factors
SGs typically contain nontranslating mRNAs, translation initiation components such as eukaryotic initiation factor
4G (eIF4G or TIF4631/TIF4632), and additional proteins affecting mRNA function including RNA-binding proteins (RBPs) and non-RNA-binding proteins [6-9].
Activated PERK phosphorylates eukaryotic initiation factor
2 (eIF2[alpha]) on Ser51 thereby blocking global protein synthesis by decreasing cap-dependent translation from most mRNAs.
Washington, August 21 ( ANI ): Researchers have discovered the way the protein, eukaryotic initiation factor
4E (eIF4E), acts upon cancer-promoting messenger RNA molecules.
In addition, 4E-BP1, an inhibitory binding partner to the eukaryotic initiation factor
4E, has been linked to muscle size regulation as its inactivation has been widely observed in both in vitro and in vivo models of cell growth (1,2,26) and has been linked to the promotion of skeletal muscle protein synthesis (2).
Proud, "Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor
4E-binding proteins," Molecular and Cellular Biology, vol.
Expression of the eukaryotic translation initiation factors
4E and 2alpha in non-Hodgkin's lymphomas.
Selective stimulation of translation of leaderless mRNA by initiation factor
2: evolutionary implications for translation.
However, further efforts are needed to fully elucidate the mechanism of initiation through interactions with either canonical initiation factors
or their homologs and to more tightly link eIF4E2 to high-risk, metastatic cancer disease.
Deregulation of translation initiation factors
is implicated extensively in cancer progression, and there is a great deal of interest in developing inhibitors targeting these factors (Lindqvist and Pelletier, 2009; Robert and Pelletier, 2009).